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ABSTRACT Chronic hepatitis B (CHB), chronic hepatitis C (CHC), and associated hepatocellular carcinoma (HCC) are charac-
terized by cholesterol imbalance and dyslipidemia; however, the key regulatory drivers of these phenotypes are incompletely
understood. Using gene expression microarrays and high-throughput sequencing of small RNAs, we performed integrative anal-
ysis of microRNA (miRNA) and gene expression in nonmalignant and matched cancer tissue samples from human subjects with
CHB or CHC and HCC. We also carried out follow-up functional studies of specific miRNAs in a cell-based system. These studies
led to four major findings. First, pathways affecting cholesterol homeostasis were among the most significantly overrepresented
among genes dysregulated in chronic viral hepatitis and especially in tumor tissue. Second, for each disease state, specific miRNA
signatures that included miRNAs not previously associated with chronic viral hepatitis, such as miR-1307 in CHC, were identi-
fied. Notably, a few miRNAs, including miR-27 and miR-224, were components of the miRNA signatures of all four disease
states: CHB, CHC, CHB-associated HCC, and CHC-associated HCC. Third, using a statistical simulation method (miRHub) ap-
plied to the gene expression data, we identified candidate master miRNA regulators of pathways controlling cholesterol homeo-
stasis in chronic viral hepatitis and HCC, including miR-21, miR-27, and miR-33. Last, we validated in human hepatoma cells
that both miR-21 and miR-27 significantly repress cholesterol synthesis and that miR-27 does so in part through regulation of
the gene that codes for the rate-limiting enzyme 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase (HMGCR).
IMPORTANCE Hepatitis B virus (HBV) and hepatitis C virus (HCV) are phylogenetically unrelated hepatotropic viruses that
persistently infect hundreds of millions of people world-wide, often leading to chronic liver disease and hepatocellular carci-
noma (HCC). Chronic hepatitis B (CHB), chronic hepatitis C (CHC), and associated HCC often lead to cholesterol imbalance
and dyslipidemia. However, the regulatory mechanisms underlying the dysregulation of lipid pathways in these disease states are
incompletely understood. MicroRNAs (miRNAs) have emerged as critical modulators of lipid homeostasis. Here we use a blend
of genomic, molecular, and biochemical strategies to identify key miRNAs that drive the lipid phenotypes of chronic viral hepati-
tis and HCC. These findings provide a panoramic view of the miRNA landscape in chronic viral hepatitis, which could contribute
to the development of novel and more-effective miRNA-based therapeutic strategies.
Received 10 September 2015 Accepted 10 November 2015 Published 8 December 2015
Citation Selitsky SR, Dinh TA, Toth CL, Kurtz CL, Honda M, Struck BR, Kaneko S, Vickers KC, Lemon SM, Sethupathy P. 2015. Transcriptomic analysis of chronic hepatitis B and C
and liver cancer reveals microRNA-mediated control of cholesterol synthesis programs. mBio 6(6):e01500-15. doi:10.1128/mBio.01500-15.
Editor Mary K. Estes, Baylor College of Medicine
Copyright © 2015 Selitsky et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-ShareAlike 3.0 Unported
license, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.
Address correspondence to Praveen Sethupathy, praveen_sethupathy@med.unc.edu.
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are non-cytopathic viruses that both exhibit marked tropism for liver
parenchymal cells and persistently infect hundreds of millions of
people world-wide, often leading to chronic liver disease and can-
cer (1). Together, these viral infections are responsible for ~80%
of hepatocellular carcinoma (HCC), which is the third leading
cause of cancer-related deaths. Though HBV and HCV are phylo-
genetically unrelated viruses, chronic infections with either virus
can lead to dyslipidemia and cholesterol imbalance (2–5). Liver
cancer is also associated with aberrant lipid and lipoprotein me-
tabolism (6, 7). While some of the molecular features of this phe-
notype have been described, including altered transcriptional ac-
tivity of sterol regulatory element-binding protein 1 (SREBP1) in
chronic HCV infection (8), the pathogenic mechanisms, in par-
ticular the roles of microRNAs (miRNAs), underlying dysregula-
tion of cholesterol pathways in chronic hepatitis C (CHC), and
especially chronic hepatitis B (CHB) and HCC, remain poorly
understood.
miRNAs, which are small RNAs that posttranscriptionally reg-
ulate gene expression, have emerged as critical modulators of lipid
homeostasis (9–11). The first miRNA that was reported to control
lipid pathways in the liver was miR-122 (12), which was also sub-
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sequently shown to promote HCV replication (13). Since the dis-
covery of miR-122, several other miRNAs have been implicated in
the control of lipid homeostasis. For example, miR-34a contrib-
utes to hepatic steatosis via regulation of sirtuins (14), miR-33
controls cholesterol flux through regulation of ATP-binding cas-
sette transporters (15–17), miR-30 regulates lipoprotein secretion
by repressing microsomal triglyceride transfer protein (18), and
miR-29 fine-tunes the FOXA2-controlled gene network govern-
ing lipid homeostasis (19). We hypothesize that miRNAs play a
key role in the lipid imbalance that has been observed in chronic
viral hepatitis and associated HCC.
In this study, we performed an integrative analysis of miRNA
and gene expression profiles in nonmalignant and matched cancer
tissue samples from patients with CHB or CHC and associated
HCC. This study represents only the second sequencing-based
profiling of miRNAs in chronic viral hepatitis. We report four
major findings. First, we established that cholesterol synthesis and
metabolism pathways are among the most dominantly altered in
each of the disease states, particularly HCC. Second, for each dis-
ease state, we defined distinct liver miRNA signatures that in-
cluded miRNAs not previously associated with viral hepatitis.
Third, we identified by integrative analysis of small-RNA and
mRNA expression data a suite of miRNAs that represent candi-
date drivers of the altered cholesterol pathways in chronic viral
hepatitis. Fourth, we validated through cell-based assays that miR-
27, which is prominently dysregulated in both CHB and CHC as
well as in HCC, significantly represses cholesterol synthesis in part
through regulation of the gene that codes for the rate-limiting
enzyme 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA)
reductase (HMGCR).
RESULTS
Pathways mediating cholesterol homeostasis are prominently
altered in chronic viral hepatitis and liver cancer. We interro-
gated previously described gene expression microarray data sets
from matched cancer and noncancer liver tissue samples collected
from Japanese adults with chronic hepatitis B (CHB) (n  10) or
chronic hepatitis C (CHC) (n  16) and chronic HCC (chronic
hepatitis B-associated cancer [c-CHB] [n  10] and chronic hep-
atitis C-associated cancer [c-CHC] [n  16]) as well as uninfected
controls (n  9) (see Tables S1 and S2 in the supplemental mate-
rial) (20, 21). Correlation analyses of gene expression profiles
showed that all samples within each disease category were highly
correlated with each other (Fig. 1A), although the cancer tissue
samples were less strongly correlated (c-CHB median pairwise
r2  0.86; c-CHC median pairwise r2  0.88) than the nonmalig-
nant CHB and CHC samples (median pairwise r2  0.96 and r2 
0.95, respectively).
FIG 1 Global gene expression in chronic viral hepatitis and cancer. (A and B) Pearson correlation coefficient heat maps. Each cell in the map represents the
correlation in expression profiles between two samples. Cells along the diagonal line represent identical samples and are shown in white. Black lines divide each
disease group. The midpoint for color bar r2 is 0.5. (A) Data from microarray analyses include only genes with average normalized expression of 1,000 (n 
8,162) in uninfected controls (n  9), CHB and matched c-CHB (n  10 each), and CHC and matched c-CHC (n  16 each). (B) The Cancer Genome Atlas
RNA-seq data include genes with an average normalized read count of 50 (n  13,017) in each disease category: c-CHB (n  12), CHB (n  6), c-CHC (n 
18), and CHC (n  5). (C and D) Analysis of differentially expressed (DE) genes in each disease category compared to the uninfected controls with a fold change
of 2 and ANOVA P value of 0.05 after Benjamini-Hochberg step-up multiple testing correction. (C) Number of DE genes. (D) Proportional Venn diagrams
comparing the DE genes of the different disease groups.
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We then repeated this analysis using publically available RNA
sequencing data from The Cancer Genome Atlas (TCGA) (http://
cancergenome.nih.gov/) for 18 c-CHB tissue samples and 6
matched CHB tissue samples as well as 18 c-CHC tissue samples
and 5 matched CHC tissue samples. We again found that the can-
cer tissue samples were more poorly correlated (c-CHB median
pairwise r2  0.58; c-CHC median pairwise r2  0.70) with each
other compared to the noncancer tissue samples (median pairwise
r2  0.98) (Fig. 1B). The weaker pairwise correlations among
c-CHB and c-CHC samples in the TCGA cohort compared to the
microarray cohort may be due at least in part to the much higher
dynamic range of expression provided by deep sequencing relative
to microarray (22), as well as increased genetic heterogeneity (due
to representation from several different ancestries) among indi-
viduals in the TCGA cohort relative to the Japanese cohort.
Next, using the microarray data from the Japanese cohort, we
identified genes that were significantly differentially expressed
(DE) in each of the four disease categories compared to the unin-
fected controls (see Table S2 in the supplemental material). We
found that CHB and c-CHB had twice as many DE genes than
CHC and c-CHC, respectively (Fig. 1C). Also, c-CHB and c-CHC
had ~3-fold-more DE genes than their nonmalignant counter-
parts (Fig. 1C). For both CHB and CHC, 60% of DE genes were
also significantly altered in the matched cancer tissue samples
(Fig. 1D). While only 17% of DE genes in CHC were also shared
with CHB, 82% of DE genes in c-CHC were shared with c-CHB
(Fig. 1D).
To determine the pathways that are most affected in each dis-
ease category, we performed Ingenuity Pathway Analysis (IPA).
We found that the DE genes in CHB and CHC were most signifi-
cantly overrepresented in distinct immune response pathways
(Table 1). For genes uniquely DE in CHB, the most enriched path-
way was CD28 signaling, which is critical for T-cell activation and
the production of interleukins (23). For genes uniquely DE in
CHC, the most enriched pathway was interferon signaling, which
is critical to innate immunity (24). For genes DE in both CHB and
CHC, the most enriched pathways were related to lipid metabo-
lism, including liver X receptor (LXR)/retinoid X receptor (RXR)
activation, which plays a central role in cholesterol homeostasis
(25–27). Lipid-related pathways were even more prevalent among
the DE genes in c-CHB and c-CHC (Table 2). For both CHB and
CHC, the top three most significantly affected pathways were re-
lated to the function of RXR, which together with LXR and FXR
regulates cholesterol balance. For genes DE in both c-CHB and
c-CHC, another significantly enriched pathway was aryl hydro-
carbon receptor (AHR) signaling, which is involved in the sup-
TABLE 1 Top 10 most significantly enriched pathways by pathway enrichment analysis of chronic viral hepatitis
Most significantly enriched pathway (P value) using DE genes from the following disease group(s)a:
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a Top ten most significantly enriched pathways from Ingenuity Pathway Analysis using either all differentially expressed (DE) genes of a disease group (“all”), DE genes of a disease
group with no overlap with any other group (“only”), or DE genes shared between two disease groups (“overlap”). Abbreviations: PRRs, pattern recognition receptors; iNOS,
inducible nitric oxide synthase; CXCR4, chemokine (C-X-C motif) receptor 4; CTLA4, cytotoxic T lymphocyte-associated protein 4; MSP, macrophage-stimulating protein;
TREM1, triggering receptor expressed on myeloid cells 1; PRPP, phosphoribosyl pyrophosphate; PDGF, platelet-derived growth factor.
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pression of hepatic cholesterol synthesis (28). Indeed, we found
that many of the genes that code for enzymes in the cholesterol
synthesis pathway were downregulated in all disease categories
compared to uninfected controls (Fig. 2).
Small-RNA transcriptome analysis identifies novel differen-
tially expressed microRNAs in chronic viral hepatitis and liver
cancer. Next we performed small-RNA sequencing in four liver
samples from each of the disease categories in the Japanese cohort
(uninfected controls, CHB, c-CHB, CHC, and c-CHC). Seven out
of the 8 c-CHB and c-CHC samples were matched with their cor-
responding nonmalignant samples. We obtained an average of
~18 million reads from each, of which ~70% mapped to the ge-
nome (see Table S3 in the supplemental material). miRNAs and
their isomiRs (sequence variants of canonical miRNAs with a dif-
ferent seed sequence) were annotated and quantified by our pre-
viously described small-RNA transcriptome sequencing (small-
RNA-seq) analysis pipeline (Materials and Methods). Within-
category correlation analyses of miRNA expression profiles
showed that uninfected controls were highly correlated (median
pairwise r2  0.98), and as in the case of gene expression (Fig. 1A
and B), the c-CHB samples were the most poorly correlated (me-
dian pairwise r2  0.70) (Fig. 3A).
We repeated this analysis using publically available small-RNA
sequencing data from TCGA (http://cancergenome.nih.gov/) for
12 c-CHB tissue samples and 6 matched CHB tissue samples as
well as 18 c-CHC tissue samples and 5 matched CHC tissue sam-
TABLE 2 Top 10 most significantly enriched pathways by pathway enrichment analysis of cancer
Most significantly enriched pathway (P value) using DE genes from the following disease group(s)a:









































































































































































a Top ten most significantly enriched pathways from Ingenuity Pathway Analysis using either all differentially expressed (DE) genes of a disease group (“all”), DE genes of a disease
group with no overlap with any other group (“only”), or DE genes shared between two disease groups (“overlap”). Abbreviations: LPS, lipopolysaccharide; RAR, retinoid acid
receptor.
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ples. These patients represent a subset of the individuals for whom
RNA-seq data were available and analyzed (Fig. 1B). We quanti-
fied miRNAs according to our previously described small-RNA
RNA-seq analysis pipeline (29) and confirmed that the cancer
tissue samples were more poorly correlated (c-CHB median pair-
wise r2  0.83; c-CHC median pairwise r2  0.79) with each other
compared to the noncancer tissue samples (median pairwise r2 of
0.95) (Fig. 3B).
Next, using the small-RNA-seq data from the Japanese cohort,
we identified DE miRNAs in each of the disease categories com-
pared to the uninfected controls (Materials and Methods). The
cancer tissue samples (c-CHB and c-CHC) had a greater number
of DE miRNAs than the noncancer tissue samples (CHB and
CHC) (Fig. 3C). Among the cancer tissue samples, c-CHB had the
greatest number of DE miRNAs (Fig. 3C). For each of CHB and
CHC, ~60% of DE miRNAs were also altered in the matched
cancer tissue samples (Fig. 3D). While only 35% of DE miRNAs in
CHC were also shared with CHB, 67% of the DE miRNAs in
c-CHC were shared with those in c-CHB (Fig. 3D).
Figure 4 shows all 134 miRNAs that were DE in at least one
disease category compared to uninfected controls. Of these 134
miRNAs, 10 (miR-378a-3p, miR-486-5p, miR-148a-3p, miR-
148a-5p, miR-27a-3p, miR-146b-5p, miR-21-3p, miR-99b, miR-
221, and miR-224) were DE in all four disease categories com-
pared to the uninfected controls. Several of these, including miR-
378a-3p and miR-27a-3p, have been associated previously with
cholesterol homeostasis (9). Using an automated PubMed litera-
ture search (Materials and Methods), we determined that among
the miRNAs that were DE in at least one disease category, the one
most studied in hepatitis and associated liver disease is miR-122
(Fig. 4), which has also previously been shown to influence lipid
metabolism (12). Although miR-122-5p, which promotes HCV
replication (13), did not satisfy our criteria for differential expres-
sion, miR-122-3p was substantially decreased in CHB, c-CHB,
and CHC (Fig. 4). While miR-122-3p is relatively understudied
compared to miR-122-5p, we found that it was robustly expressed
in all of the liver tissue samples (see Fig. S1 in the supplemental
material). We also found that miR-122-3p coimmunopurifies
with Argonaute 2 (AGO2) in extracts from human hepatoma cells
(FT3-7) (20) and that its abundance in AGO2 immunoprecipi-
tates is proportional to total intracellular levels, indicating effi-
cient loading (Fig. S1). These data suggest that despite the exten-
sive focus in the literature on miR-122-5p, miR-122-3p is likely
also a functional miRNA and merits further detailed experimental
investigation.
We identified several previously reported DE miRNAs, includ-
ing miR-21 (30), miR-27 (31), and miR-181 (32) in CHC, miR-
199 (33), miR-148 (34), and miR-125 (35) in CHB, and miR-221/
222 (36), miR-101 (37), and miR-224 (38) in chronic viral
hepatitis-associated liver cancer. Many of the other DE miRNAs
that we identified, such as miR-215 and miR-340 in CHB, miR-
1307 and miR-484 in CHC, and miR-136-5p and miR-3591-5p in
c-CHC, have not been well studied in the liver. All of these miR-
NAs represent candidate regulators of the pathways altered in
chronic viral hepatitis and liver cancer, including those governing
cholesterol synthesis and metabolism.
Several microRNAs are identified as candidate master regu-
lators of pathways mediating cholesterol homeostasis in
chronic viral hepatitis and liver cancer. We next sought to iden-
tify DE miRNAs that represent potential key control points (mas-
ter regulators) in the networks that regulate gene expression in
chronic viral hepatitis and cancer. Using our previously developed
tool miRHub (Materials and Methods), we identified 21 candidate
master miRNA regulators of genes downregulated in at least one
disease group: CHB, c-CHB, CHC, or c-CHC (Fig. 5A). Among
these 21, six were predicted to be master regulators in at least two
different disease categories: miR-33, miR-199-3p, miR-194, miR-
450b, miR-23, and miR-27-3p (Fig. 5A). miR-33, miR-199-3p,
miR-450b, and miR-27-3p were upregulated in c-CHB and
c-CHC (Fig. 4) and identified as potential master regulators of
downregulated genes in the same disease categories (Fig. 5A). Al-
though hepatic miR-33 is a known regulator of cholesterol ho-
meostasis, it has only recently been studied in the context of
chronic viral hepatitis and HCC (39). Both miR-199-3p and miR-
27-3p are among the few miRNAs that have been reported as
regulators of phenotypes associated with chronic viral hepatitis
(cancer [40] and dyslipidemia [41, 42], respectively). miR-194
and miR-23 were downregulated in the same disease categories for
which they were predicted as master regulators of downregulated
genes. This finding is suggestive of transcriptional coregulation of
miR-194/miR-23 and their target genes, consistent with the par-
ticipation of these miRNAs in complex regulatory motifs (43).
We also identified eight candidate master miRNA regulators of
upregulated genes in at least one of the disease categories (Fig. 5B).
Interestingly, all eight miRNAs were upregulated in the same dis-
ease categories for which they were predicted to be master regula-
tors of upregulated genes. As with miR-194 and miR-23, one pos-
sible explanation for this finding is the widespread use of
incoherent feed-forward miRNA loops in liver gene regulatory
networks (43).
The strongest candidate master miRNA regulators in any dis-
FIG 2 Expression of genes in the cholesterol synthesis pathway in chronic
viral hepatitis and cancer. Log2 of average fold change in each disease group
(CHB, c-CHB, CHC, and c-CHC) compared to uninfected controls for genes
that code for major enzymes within the cholesterol biosynthesis pathway. Due
to decreasing reliability from “_at,” “_s_at,” to “_x_at” for genes with multiple
probe types, the most reliable annotations are displayed. Results are shown for
“_s_at” only if “_at” were not available and for “_x_at” probes only if “_s_at”
or “_at” probes were not available. HMGCS1, HMG-CoA synthase 1;
HMGCR, HMG-CoA reductase; MVK, mevalonate kinase; PMVK, phospho-
mevalonate kinase; MVD, mevalonate decarboxylase; IDI1, isopentenyl-
diphosphate delta isomerase 1; FDPS, farnesyl diphosphate synthase; FDFT1,
farnesyl-diphosphate farnesyltransferase 1; SQLE, squalene epoxidase; LSS,
lanosterol synthase; CYP51A1, cytochrome P450 family 41 subfamily A;
TM7SF2, transmembrane 7 superfamily member 2; NSDHL, NAD(P)-
dependent steroid dehydrogenase-like; HSD17B7, hydroxysteroid 17-beta de-
hydrogenase; DHCR24, 24-dehydrocholesterol reductase; SC5D, sterol-C5-
desaturase; DHCR7, 7-dehydrocholesterol reductase.
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ease category were miR-21 and miR-33, which were both upregu-
lated in c-CHB (Fig. 4) and predicted to exert greater control of
downregulated genes in c-CHB than any other miRNA (Fig. 5A).
miR-21 has been reported previously as a critical mediator of
c-CHB and suppressor of the host immune system in CHC (30).
miR-33 is a key regulator of cholesterol homeostasis and has re-
cently been associated with hepatic steatosis and fibrosis in pa-
tients with CHC and CHB, respectively (39).
For each miRNA predicted as a candidate master regulator of
up- or downregulated genes in each disease category, we identified
biological pathways significantly enriched among its predicted
target genes (see Table S4 in the supplemental material). We
found that most candidate master regulator miRNAs were pre-
dicted to target genes overrepresented in pathways regulating lipid
homeostasis. For example, among downregulated genes in
c-CHB, 12 of the 13 candidate master miRNA regulators were
predicted to target genes significantly overrepresented in the per-
oxisome proliferator-activated receptor  (PPAR)/RXR acti-
vation pathway. Several of these 12 candidate master miRNA reg-
ulators, including miR-21 and miR-33, have been recently
reported as direct modulators of PPAR expression (44), and
miR-27-3p has been shown to target and repress both PPAR (44)
and RXR (45). Transcriptional regulation by PPAR/RXR
contributes to hepatic control of lipid biosynthesis (46, 47). These
findings lead to the hypothesis that several key miRNAs mediate
the robust suppression of cholesterol synthesis pathways in
chronic viral hepatitis and associated liver cancer.
miR-27 suppresses cholesterol synthesis via regulation of the
rate-limiting enzyme HMG-CoA reductase. The evaluation of
this hypothesis is hindered by a lack of cell culture models that
accurately recapitulate virus-host interactions in vivo during HBV
or HCV infection. Nonetheless, to determine whether the DE
miRNAs are capable of regulating cholesterol synthesis in liver
cancer cells, we selected miR-21, miR-27, and miR-224 for func-
tional follow-up analyses in human hepatoma cells (Huh7). As a
control for these experiments, we similarly evaluated miR-151,
which our computational analyses did not identify as a master
regulator. Specifically, we overexpressed each miRNA at a stan-
dard effective concentration (see Fig. S2 in the supplemental ma-
terial) separately in Huh7 cells grown in lipoprotein-deficient se-
rum and evaluated the effect on de novo cholesterol synthesis
(Materials and Methods). We found that all three DE miRNAs,
but not the control miR-151, suppressed cholesterol synthesis to
various degrees (Fig. 6A). Interestingly, all three of these miRNAs
have at least one predicted seed sequence target site in the 3= un-
translated region (UTR) of the HMG-CoA reductase (HMGCR)
FIG 3 Global miRNA expression in chronic viral hepatitis and cancer. (A and B) Pearson correlation coefficient heat maps. Each cell in the map represents the
correlation in expression profiles between two samples. Cells along the diagonal represent identical samples and are shown in white. Black lines divide each
disease group. The midpoint for color bar r2 is 0.5. (A) miRNAs included are those from small-RNA sequencing with average reads per million mapped (RPMM)
of 100 (n  208) in uninfected controls (n  4), CHB (n  4), matched c-CHB (n  4), CHC (n  4), and matched c-CHC (n  4) tissue samples. (B) miRNAs
from The Cancer Genome Atlas small-RNA-seq with an overall average RPMM of 100 (n  180) in each disease category: CHB (n  6), c-CHB (n  12), CHC
(n  5), and c-CHC (n  15). (C and D) Analysis of differentially expressed (DE) miRNAs in each disease category compared to the uninfected controls,
including only miRNAs that have the following characteristics: (i) RPMM of 50, (ii) a fold change of 1.5, and (iii) changes in the same direction for at least
3 out of 4 samples from each disease group. 5=-shifted isomiRs (sequence variants of canonical miRNAs with a different seed sequence) are included in this
analysis. (C) Number of DE miRNAs. (D) Proportional Venn diagrams comparing the DE miRNAs of different disease groups.
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gene (Fig. 6B), which encodes the rate-limiting enzyme in the
cholesterol synthesis pathway. The predicted target sites for
miR-27 and miR-224 are conserved across several mammalian
species, whereas the predicted site for miR-21 is found only in
humans (Fig. 6B).
HMGCR mRNA was significantly decreased in all four disease
categories, whereas miR-27 and miR-224 were significantly ele-
vated in all four disease categories, and miR-21 was increased in
c-CHB and CHC (Fig. 6C). We have shown previously that
miR-27 represses HMGCR expression in hepatoma cells (41), and
another study using mouse brain tissue suggested that miR-27
may regulate HMGCR directly by targeting its 3=UTR (48). To test
this hypothesis, we performed a 3=UTR reporter gene assay. Spe-
cifically, the entire HMGCR 3=UTR was PCR amplified from hu-
man genomic DNA and cloned into the PsiCheck2 expression
vector, downstream of the Renilla luciferase (RL) coding region
(Materials and Methods). The recombinant PsiCheck2 vector was
then transfected into HEK293T cells, and relative RL activity was
measured in the presence and absence of oligonucleotide mimics
of miR-27 or a negative-control miRNA (miR-375, which is not
predicted to have a target site in the HMGCR 3= UTR). The
miR-27 mimic induced significant repression (Fig. 6D), whereas
FIG 4 Published literature on miRNAs that are differentially expressed in chronic viral hepatitis and liver cancer. (Left of each panel shown) Heat map of
significantly differentially expressed miRNAs in each disease group (CHB, c-CHB, CHC, and c-CHC) compared to the uninfected controls that have the
following characteristics: (i) an average fold change of 1.5 in one disease state, (ii) a change in the same direction in at least 3 out of 4 samples within each disease
group, and (iii) reads per million mapped reads (RPMM) of 50 in at least one disease group. The color represents log2 (average fold change) compared to the
uninfected controls. Black boxes indicate that the miRNA for a specific disease state did not fit the criteria of DE (center and right of each panel shown). Results
of automated searches of PubMed on 5 December 2014 using the following search terms for the miRNA: e.g., “miRNA-X,” “miR-X,” or “microRNA-X” with or
without the miRNA family letter (e.g., for miR-148a, “miRNA-148a,” “miR-148a,” “microRNA-148a,” “miRNA-148,” “miR-148,” or “microRNA-148”]) and
ignoring the “-3p” or “-5p.” (Center) Number of total published papers indexed on PubMed based on searches of just the miRNA name. The color bar midpoint
at 100 is shown on the right. Proportion of total published papers related to each miRNA that was associated with liver (search term “liver”), HBV (search term
“hepatitis B” or “HBV”), HCV (search term “hepatitis C” or “HCV”), or hepatocellular carcinoma (search term “HCC,” “hepatocellular,” or “liver cancer”).
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miR-375 had no effect. We then introduced a mutation in the
miR-27 target site via site-directed mutagenesis and demonstrated
a partial but still significant (P  0.01) rescue of relative RL activ-
ity.
Model of miRNA-mediated regulation of cholesterol metab-
olism in chronic viral hepatitis and associated HCC. At least nine
genes in the cholesterol synthesis pathway were significantly
downregulated in at least one disease category. Of these nine
genes, five (HMGCS1, HMGCR, NSDHL, DHCR24, and SC5DL)
have evolutionarily conserved predicted target sites for 2 miR-
NAs that were upregulated more than 5-fold in at least one disease
category and/or identified as master regulators of downregulated
genes in at least one disease category (Fig. 7; see Fig. S3 in the
supplemental material). Predicted target sites for miR-499 and
miR-224 are shared among two of the genes (HMGCS1/HMGCR
and HMGCR/SC5DL, respectively), and three genes (HMGCS1,
HMGCR, and SC5DL) harbor putative target sites for miR-27.
These three miRNAs represent key direct regulators of the choles-
terol synthesis pathway in chronic viral hepatitis and associated
liver cancer.
The LXR/RXR regulatory pathway is significantly enriched
among dysregulated genes in many of the disease groups (Ta-
ble 2). This pathway is involved in the control of several aspects of
cholesterol metabolism, most notably cholesterol efflux (see
Fig. S4 in the supplemental material). Numerous genes in the
cholesterol efflux and transport pathway are significantly down-
regulated in at least one disease state, including ABCA1, also
known as cholesterol efflux regulatory protein (CERP), which is a
direct target of LXR/RXR and is significantly decreased in expres-
sion in c-CHB and c-CHC. ABCA1 is predicted to be a target gene
of 15 miRNAs that are upregulated in at least one disease state
(c-CHB or c-CHC), including miR-33 and miR-27, which are
established regulators of cholesterol efflux through suppression of
ABCA1 (42, 49).
DISCUSSION
On the basis of gene expression microarray data, we found path-
ways relating to cholesterol synthesis and metabolism to be the
most significantly enriched among genes dysregulated in the var-
ious disease states we studied, especially c-CHB and c-CHC. In-
terestingly, in the noncancer tissue samples, although immune
pathways were the most significantly enriched, the specific im-
mune pathways were different for CHB and CHC, which is con-
sistent with distinct inflammatory features and innate immune
responses in each disease. The top enriched immune pathway for
CHC is interferon signaling, and for CHB, the top pathways are
associated with both the innate and adaptive immune responses,
although not interferon signaling. Some pathways, such as those
controlling blood flow and coagulation (c-CHB and c-CHC), as
well as amino acid degradation (c-CHB), merit future investiga-
tion.
Studies of miRNAs in hepatitis C have been dominated by
miR-122-5p, and only a few other miRNAs have been investi-
gated. miR-122-5p was previously found to be reduced in patients
with chronic hepatitis C, but the reduction was dependent on the
interleukin 28B (IL-28B) genotype (20). In this study, we per-
formed small-RNA-seq on two subjects from each IL-28B geno-
type class (T/T and T/G, based on SNP rs8099917). Similar to
what was reported previously (20), miR-122 levels were reduced
only in the individuals with the T/G genotypes and not the T/T
genotype. Because our criteria for DE stipulated that the levels of a
miRNA must change significantly and in the same direction in
three of the four samples in a disease group, miR-122-5p was not
deemed to be DE in our study.
FIG 5 Candidate miRNA master regulators of gene expression profiles in chronic viral hepatitis and associated liver cancer. (A and B) Heat map of the
–log10(P value) of the predicted targeting score for each miRNA (determined using miRHub) among genes deregulated in each disease category (CHB, c-CHB,
CHC, and c-CHC) compared to uninfected controls. Only miRNAs with an empirical P value of 0.05 (based on miRHub Monte Carlo simulation) in at least
one disease group are shown. Black boxes indicate that the miRNA for a specific disease state did not fit the criteria of DE. (A) Candidate miRNA master regulators
of significantly downregulated genes in each disease category. (B) Candidate miRNA master regulators of significantly upregulated genes in each disease category.
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Our study points to the potential functional relevance of miR-
122-3p, which has received substantially less attention due to its
lower expression than miR-122-5p, but we find that its expression
is robust and that it is effectively loaded and abundantly present
on AGO2. miR-122-3p was not a predicted miRNA master regu-
lator of gene expression in any of the disease states, but it does have
several key predicted mRNA targets, including the interferon-
stimulated gene, interferon-induced protein with tetratricopep-
tide repeats 3 (IFIT3). We also show that a suite of other miRNAs,
including miR-27, miR-33, miR-21, and miR-199, are differen-
tially expressed in one or more of the disease states and also are
predicted to be master regulators of the disease gene expression
profiles.
We showed that several of these “master regulator” miRNAs,
notably miR-33, miR-21, and miR-27, are strongly associated with
liver programs that control cholesterol homeostasis. Since miR-33
is already well established as a modulator of cholesterol metabo-
lism, we focused our functional studies on miR-27 and miR-21, as
well as miR-224, which were among the most highly upregulated
miRNAs in all disease states. While miR-21 and miR-27 have been
linked to lipid homeostasis previously (42, 50, 51), we have shown
here that miR-27 and miR-21 both significantly suppress de novo
cholesterol synthesis in Huh7 cells by ~30% and ~70%, respec-
tively. Furthermore, we demonstrated that the effect of miR-27 is
mediated in part through direct regulation of the HMGCR gene,
which encodes the rate-limiting enzyme in cholesterol biosynthe-
sis. Specifically, in a reporter gene assay in which the HMGCR 3=
UTR was cloned downstream of a luciferase gene, we showed that
overexpression of miR-27 markedly reduced luciferase activity
and that a mutation in the target site of miR-27 within the
HMGCR 3=UTR significantly rescued luciferase activity. We note
that the rescue was not complete, and there are several possible
FIG 6 Candidate miRNA master regulators miR-27 and miR-21 control cholesterol synthesis in vitro. (A) Human hepatoma (Huh7) cells transfected with a
10 nM concentration of either miRNA mimic or transfection reagent alone (mock transfected) for the different RNAs: for miR-151, mock (n  6) and mimic (n
 3); for miR-27, mock (n  6) and mimic (n  6); for miR-21, mock (n  6) and mimic (n  6); for miR-224, mock (n  5) and mimic (n  5). De novo
cholesterol synthesis was measured by radiolabeled acetate incorporation assay (Materials and Methods). Relative change compared to mock transfection is
shown. (B) Predicted target sites in the HMGCR 3= UTR for miR-27, miR-21, and miR-224 as determined by the TargetScan algorithm. Gaps introduced to
maximize alignment are indicated by dashes. (C) Relative levels of HMGCR mRNA, miR-21, miR-27, and miR-224 across the disease categories. Fold change
values for HMGCR are based on comparison to the values for uninfected controls. RPMM, reads per million mapped reads. (D) Effects of miR-27 mimic (10 nM)
and miR-375 (10 nM; negative control) on the activity of Renilla (RL) luciferase containing either wild-type (WT) or mutated (Mut) HMGCR 3=UTR normalized
to firefly luciferase (FL) in transfected Huh7 cells. Each condition was tested twice with three technical replicates each (total n  6). The mutation was targeted
to the predicted miR-27 target site. P values were determined using two-tailed unpaired Student’s t test and are indicated as follows: *, P  0.05; ***, P  0.005.
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explanations for this observation. For example, miR-27 may have
additional noncanonical target sites within HMGCR (even within
its open reading frame) that are not predicted by current bioin-
formatics methods; such sites would, of course, remain functional
even when a mutation is introduced in the canonical target site.
Very few studies have linked miRNAs to the direct regulation of
HMGCR. Both miR-27 and miR-21 may be candidate therapeutic
targets for hypercholesterolemia.
We found that the LXR/RXR pathway was prominently dys-
regulated in all disease states. This nuclear receptor pathway has
known functions in the regulation of both lipid metabolism and
immune and inflammatory responses. For example, recent in vivo
studies have shown that LXR activation promotes cholesterol ef-
flux and inhibits inflammation in part by suppressing NF-B sig-
naling (52–54). For most of the disease states we studied, well-
established LXR target genes, such as CYP7A1 and ABCA1, were
downregulated, whereas genes promoted by NF-B signaling
were upregulated (Table 1). More-detailed analysis is required to
determine the roles of miRNAs in controlling LXR/RXR in vivo
during chronic viral hepatitis and thereby integrating lipid meta-
bolic and inflammatory signaling.
CHB, CHC, and HCC have all been linked to cholesterol and
lipid imbalance; however, much remains unknown about the un-
derlying molecular mechanisms, particularly with regard to miR-
NAs. Through integrative analysis of small-RNA-seq and mi-
croarray data and follow-up validation experiments in a cell-based
system, our study provides important clues about the candidate
miRNA drivers of this phenotype. In terms of CHC, the results of
our studies are most applicable to HCV genotype 1, because the
tissue samples we analyzed were primarily from patients infected
with this strain. Similar studies are warranted in CHC resulting
from infections by other HCV genotypes, in particular genotype 3,
which has been associated with fatty liver disease and which may
have unique, genotype-specific interactions with host genes (55,
56). It is important to note that we did not study liver tissue from
individuals with nonviral liver diseases, such as alcoholic hepatitis
or nonalcoholic fatty liver disease. Future studies with such sam-
ples will help determine whether the miRNAs that we found to be
associated with hepatitis and HCC in this study are specific to viral
hepatitis or shared across other types of hepatic disease. Also, fu-
ture investigations should focus on more-detailed functional
characterization of specific miRNAs of interest and their roles in
regulating cholesterol homeostasis, particularly in the back-
ground of cirrhosis and the chronic inflammation present in viral
hepatitis. As the use of locked nucleic acid (LNA) inhibitors ex-
pand, such studies may lead to the development of novel and
effective miRNA-based therapeutic strategies.
MATERIALS AND METHODS
Human subjects. Written informed consent was obtained from all hu-
man subjects. Ethics approval was obtained from the Ethics Committee
for Human Genome/Gene Analysis Research at Kanazawa University
Graduate School of Medical Science.
Gene expression analysis. Gene expression microarray data (20, 21)
for CHB, c-CHB, CHC, and c-CHC were contrasted to the uninfected
tissue samples to determine differentially expressed (DE) genes (analysis
of variance [ANOVA] P value of 0.05 after Benjamini-Hochberg
step-up multiple testing correction and fold change of 2 compared to
the uninfected tissue samples) using Partek Genomics Suite (Partek Inc.,
St. Louis, MO). Pathway enrichment was determined with Ingenuity
Pathway Analysis software (Qiagen, Hilden, Germany).
Small-RNA sequencing. RNA was isolated as described previously
(20). RNA purity was assessed with Nanodrop 2000 (Thermo Scientific,
Rockford, IL), and integrity was determined with an Agilent 2100 bioana-
lyzer (Agilent, Santa Clara, CA). RNA integrity and sequencing quality
were comparable for all specimens. Small-RNA libraries were generated
using Illumina TruSeq small-RNA sample preparation kit (Illumina, San
Diego, CA). Sequencing was performed on the Illumina HiSeq 2000 plat-
form. Sequencing reads were trimmed using Cutadapt (parameters O
10 e 0.1). Trimmed reads were mapped to genomic regions spanning
annotated miRNAs (20 nucleotides [nt]) using Bowtie 0.12.7, allowing
for no mismatches. Next, reads that did not map without mismatches
were aligned to the same regions using SHRiMP2.2.2. SHRiMP2.2.2 seeds
were set based on the length of the read allowing one mismatch anywhere
in the body and up to three mismatches at the 3= end of the read (based on
the length of the read). Small-RNA sequencing data were deposited in
GEO (accession no. GSE57381). TCGA liver cancer small RNA-seq BAM
files annotated as having a risk factor of either “hepatitis B” or “hepatitis
C” and no other annotated risk were downloaded and processed using the
bioinformatics method described above.
Automated PubMed searches. An automated search of PubMed was
performed using a Ruby program with the HTML parser Nokogiri on
5 December 2014. Search terms for the miRNAs were, for example,
“miRNA-X,” “miR-X,” or “microRNA-X” with or without the miRNA
FIG 7 Model of miRNA regulation of cholesterol synthesis in chronic viral
hepatitis and associated liver cancer. Cholesterol synthesis genes that are sig-
nificantly downregulated in at least one disease state are shown. Each miRNA
is significantly upregulated in at least one disease state relative to uninfected
controls and is either a predicted miRNA master regulator of gene expression
in at least one disease state based on miRHub P value of 0.05 or has a fold
change of 5 compared to uninfected controls. See Fig. S2 and S3 for greater
detail. HMGCS1, HMG-CoA synthase 1; HMGCR, HMG-CoA reductase;
FDPS, farnesyl diphosphate synthase; SQLE, squalene epoxidase; LSS, lanos-
terol synthase; NSDHL, NAD(P)-dependent steroid dehydrogenase-like;
DHCR24, 24-dehydrocholesterol reductase; SC5D, sterol-C5-desaturase;
DHCR7, 7-dehydrocholesterol reductase.
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family letter (e.g., miR-148a [“miRNA-148a,” “miR-148a,” “microRNA-
148a,” “miRNA-148,” “miR-148,” “microRNA-148”]). Other search
terms (search term “liver”), HBV (search term “hepatitis B” or “HBV”),
HCV (search term “hepatitis C” or “HCV”), or hepatocellular carcinoma
(search term “HCC” or “hepatocellular” or “liver cancer”).
Identification of miRNA candidate master regulators using
miRHub. To identify miRNA candidate master regulators, we used a tool
we developed previously (29), which we subsequently named “miRHub.”
We have since used miRHub successfully in several follow-up studies
(57–59), including one in which we provided a more detailed description
of the methods (57). Briefly, miRHub uses the TargetScan algorithm to
predicted target sites for miRNAs of interest in the 3= UTRs of DE genes
and then determines by Monte Carlo simulation for each miRNA whether
the number and strength of predicted targets is significantly greater than
expected by chance. Such miRNAs are designated “master regulators.”
Using miRHub, we predicted the miRNA master regulators for eight dif-
ferent gene lists (significantly DE upregulated genes in each disease group
and significantly DE downregulated genes in each disease group), using
four different miRNA lists (DE miRNAs in each disease category irrespec-
tive of their fold change direction).
Measuring cholesterol synthesis. Human hepatoma cells (Huh7)
were seeded into six-well plates at a density of 1  105 cells/ml. After
overnight growth, cells were transfected with miR-151 mimic, miR-21
mimic, miR-27 mimic, or miR-224 mimic at 10 nM each (Exiqon,
Woburn, MA), or Lipofectamine 2000 transfection reagent only (mock
transfected) (Life Technologies, Grand Island, NY). Forty-eight hours
after transfection, the medium was removed and replaced with Dulbecco
modified Eagle medium (DMEM) with low-glucose lipoprotein-deficient
serum (LPDS). Seventeen hours later, low-glucose medium was removed
and replaced with fresh serum-free low-glucose medium (cholesterol
free) with 1 Ci [3H]acetic acid per well (0.5 Ci/ml medium) and incu-
bated for 6 h. The cells were washed twice with 1 phosphate-buffered
saline. Two milliliters of 3:2 hexane-isopropanol were added to each well;
the cells were allowed to sit for 2 h and then placed in glass vials. Samples
were dried by using nitrogen, and 30 l of cold 0.1 g cholesterol-
cholesteryloleate was added. Thirty microliters of resuspended lipids was
placed on a plate, and thin-layer chromatography was performed (230:
60:3 petroleum ether-diethyl ether-acetic acid). Spots were resolved with
iodine, and cholesteryl ester, cholesterol, and triglyceride spots were cut
out and placed in 10 ml scintillation fluid. Total protein for each well was
quantified using the bicinchoninic acid (BCA) assay. Disintegrations per
minute (dpm) values were normalized to the values for total protein.
miRNA overexpression and reporter gene assays. HEK293T cells
were maintained in DMEM with 25 mM glucose (Sigma-Aldrich, St.
Louis, MO) supplemented with 10% fetal bovine serum (FBS) and 2 mM
L-glutamine (Invitrogen, Grand Island, NY) and cultured in a humidified
incubator at 37°C and 5% CO2. HEK293T cells were seeded into 24-well
plates and allowed to grow overnight. Once the cells were approximately
70% confluent, they were transfected with 200 ng of pEZX-MT01 empty
vector, vector containing the 3= UTR of HMGCR (GeneCopoeia,; Rock-
ville, MD) and 10 nM miRIDIAN microRNA hsa-miR-27b mimic (5= U
AGCACCAUCUGAAAUCGGUUA 3=, Dharmacon, Lafayette, CO) or 10
nM miRIDIAN microRNA hsa-miR-375 mimic (5=UUUGUUCGUUCG
GCUCGCGUGA 3=). Transfection was performed using Lipofectamine
2000 (Life Technologies, Grand Island, NY). After 48 h, the cells were
lysed, and luciferase activity was measured using the Luc-Pair luciferase
assay kit (Agilent, Santa Clara, CA) on a GloMax 96 microplate luminom-
eter (Promega, Madison, WI). Site-directed mutagenesis was performed
with the QuikChange II XL site-directed mutagenesis kit (Agilent, Santa
Clara, CA).
Statistics and graphics. P values were calculated and plots were gen-
erated using R and Prism. Proportional Venn diagrams were generated by
the R package “VennDiagram.”
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